OBJECTIVE:To stndy the clinical efficacy and safety of somatostatin combined with pantoprazole sodium in the treatment of severe acute pancreatitis(SAP). METHODS:By retrospective analysis,98 patients with SAP were divided into control group and observation group by the different treatment. All patients were treated by routine treatment of SAP. Based on it,patients in control group were given Pantoprazole sodium for injection 40 mg adding into 0.9% sodium chloride injection 100 ml,iv,twice a day;patients in observation group were given Somatostatin for injection 3 mg adding into 0.9% sodium chloride injection 100 ml based on the treatment of control group,by micro intravenous continuous intravenous infusion,0.25 mg/h,twice a day.Both cours-es were 7 d. The clinical data was observed,including clinical efficacy,improvement time of signs and symptoms(remission time of stomachache,recovery time of gastrointestinal function,withdrawal time of ventilator) and tumor necrosis factor-α(TNF-α), high-sensitivity C-reactive protein (hs-CRP),interleukin-8 (IL-8) levels and the incidence of adverse reactions before and after treatment. RESULTS:The total effective rate in observation group was significantly higher than control group,and the improve-ment time of signs and symptoms was significantly shorter than control group,with significant differences(P<0.05). After treat-ment,the inflammatory cytokine levels in 2 groups were significantly lower than before,and observation group was lower than con-trol group,with significant differences(P<0.05). The incidence of adverse reactions in observation group was significantly lower than control group,with significant difference(P<0.05). CONCLUSIONS:Based on the routine treatment,somatostatin combined with pantoprazole sodium has better efficacy than only pantoprazole sodium,with better safety.

Potassium metabolism in young adult men exercising in the heat for six consecutive days and the effect of potassium deficiency in mice and rats induced by low potassium diet during heat exposure were observed. Increased potassium loss in sweat and lower potassium intake resulted in negative potassium balance. Individuals with a negative potassium balance had lower se- rum potassium levels and higher body temperature after exercise. Potassium deficient mice accomplished less work done (2.372 vs 4.253 Kg.M) but exih-ibited a markedly greater rate of heat gain (1.36 vs 0.87℃/Kg.M) as compared to the controls. The survival rate and cellular energy metabolism also decreasedThese observations suggest that prevention from potassium deficiency must be emphasized during prolonged physical activity under hot environments. According to the linear regression equations between potassium intake and balance, it is proposed that the potassium requirements in mild and medium physical activity in the heat are 40 and 60 mEq/day respectively, and the allowance of potassium in the latter may be 70-80 mEq/day.

Objective To establish a method of identification of DKO mouse model of Duchenne muscular dystro-phy, and to assess the dystrophin regeneration after stem cell transplantation.Methods Heterozygous mice were mated and the resulting offspring were used to identify their genotype by SSP-PCR.The plasma creatine kinase level was measured by biochemical analyzer and histological changes in the DKO mice were analyzed using HE staining.Human umbilical cord mesenchymal stem cells were prepared and injected into the DKO mice hindlimb muscle, and dystrophin expression was de-tected by immunofluorescence staining at 2 months after injection.Results Mating of heterozygous mice generated three kinds of genotype offsprings, and 21.2%of the offsprings were identified as DKO genotype (285 bp) .DKO mice showed dystrophic symptoms, their plasma creatine kinase level was as high as 16988.52 ±617.48 IU/L, and significant histologi-cal changes including diverse myocyte sizes, numerous centrally nucleated cells and connective tissue proliferation or in-flammatory cells infiltration.Human dystrophin expression was detected in the DKO mouse hindlimb muscle at two months after injection of human umbilical cord mesenchymal stem cells.Conclusion DKO mouse genotype can be identified by SSP-PCR, and DKO mouse is an ideal animal model for studies of stem cell therapy for Duchenne muscular dystrophy.